The Benefits Of Outsourcing Your Biomanufacturing To A Polish CDMO

By Adam Pietruszkiewicz, Chief Commercial Officer, Mabion; Magdalena Kulczycka, Ph.D., Managing Director of BioForum; and Professor Tadeusz Pietrucha, Ph.D., Biotechnologist, Head of the Medical Biotechnology Department at the Medical University of Lodz

As the EU renews its commitment to biotech innovation and manufacturing, it has rolled out the Biotech and Biomanufacturing Initiative, which aims to increase competitiveness, resilience, and modernization among EU biotechs and manufacturers. As a result, EU countries like Poland offer compelling possibilities for outsourcing. Poland’s notable resources include a robust workforce with a significant portion of college graduates entering the biopharma sector; the country is ranked first in Central Eastern Europe for its number of biopharma graduates and fifth in all of Europe.

Furthermore, the cost of outsourcing to Poland is significantly less expensive when compared to much of Europe and the U.S. Though the biotech sector is relatively young, it is supported by ample innovation and collaboration between biotechs, CDMOs, academia, and networking organizations striving to enhance growth. If you are ready to learn more about the possibilities of working with a Polish CDMO, download the full article.